Clene (CLNN) vs Edesa Biotech (EDSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Edesa Biotech (EDSA) has outperformed Clene (CLNN) over the past year, gaining 34.6% versus a loss of 58.8%. Over five years, EDSA leads with a -93.3% price change compared with -96.9% for CLNN. Clene is the larger company by market cap ($55.2 million vs $49.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLNN | EDSA |
|---|---|---|
| Share price | $3.88 | $3.66 |
| Market cap | $55.15M | $49.45M |
| 1-day change | -1.02% | -5.79% |
| YTD return | -33.90% | +157.75% |
| 1-year return | -58.81% | +34.56% |
| 5-year return | -96.86% | -93.31% |
| EPS (TTM) | $-3.52 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.50 | $20.32 |
| 52-week low | $3.25 | $0.72 |
| Distance from 52-week high | -71.26% | -81.99% |
| Analyst consensus | none | none |
| Avg. price target upside | +729.90% | +346.17% |
| Average volume | 100.21K | 61.89K |
| Shares outstanding | 14.21M | 13.51M |
| Employees | 76 | 17 |
| Sector | Consumer Defensive | Healthcare |
| Industry | Packaged Foods | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed CLNN by 93.4 percentage points over the past year.
- The two companies sit in different sectors: Clene in Consumer Defensive and Edesa Biotech in Healthcare.
About Clene
CLNN stock →Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Consumer Defensive · Packaged Foods · 76 employees
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Healthcare · Biotechnology · 17 employees
CLNN vs EDSA FAQ
Which is bigger, Clene or Edesa Biotech?
Clene (CLNN) is larger, with a market capitalization of $55.15M compared with $49.45M for Edesa Biotech (EDSA).
Which stock has performed better over the past year, CLNN or EDSA?
EDSA returned +34.56% over the past 12 months, compared with -58.81% for CLNN (price return, excluding dividends). Past performance does not predict future results.
Are Clene and Edesa Biotech in the same industry?
No. Clene is in the Consumer Defensive sector, while Edesa Biotech is in Healthcare.